Opdivo (Nivolumab)

Nivolumab, the active ingredient in Opdivo, is a monoclonal antibody presented as a strength/form for intravenous use. It is indicated for the treatment of certain cancers in adult patients. GNH USA supplies Opdivo as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Opdivo as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Opdivo is a checkpoint‑inhibitor immunotherapy used in several oncology indications.

- Melanoma: Improves overall survival in patients with unresectable or metastatic disease. - Non‑small cell lung cancer (NSCLC): Extends progression‑free survival when combined with chemotherapy. - Renal cell carcinoma: Delays disease progression in advanced cases. - Classical Hodgkin lymphoma: Achieves durable responses in relapsed or refractory disease. - Head and neck squamous cell carcinoma (HSC        ).

It           

{"metatitle":"Opdivo        ","}]":null}